Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 14/20 | 0.82 |
| ▸ | CTSB | P07858 | 4/20 | 0.51 |
| ▸ | CTSS | P25774 | 4/20 | 0.51 |
| ▸ | CTSL | P07711 | 2/20 | 0.51 |
| ▸ | CTSK | P43235 | 3/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6004042 | 1.00 | TGM2 (0.82) | TGM2CTSBCTSSCTSLCTSK | |
| SCHEMBL4929220 | 1.00 | TGM2 (0.82) | TGM2CTSBCTSSCTSLCTSK | |
| SCHEMBL13934076 | 0.90 | TGM2 (1.00) | TGM2CTSBCTSSCTSLCTSK | |
| SCHEMBL1103744 | 0.90 | TGM2 (1.00) | TGM2CTSBCTSSCTSLCTSK | |
| SCHEMBL4395083 | 0.90 | TGM2 (1.00) | TGM2CTSBCTSSCTSLCTSK | |
| SCHEMBL4397819 | 0.90 | TGM2 (1.00) | TGM2CTSBCTSSCTSLCTSK | |
| SCHEMBL4302758 | 0.90 | TGM2 (1.00) | TGM2CTSBCTSSCTSLCTSK | |
| SCHEMBL13934064 | 0.90 | TGM2 (1.00) | TGM2CTSBCTSSCTSLCTSK | |
| SCHEMBL1091124 | 0.86 | TGM2 (0.93) | TGM2CTSBCTSSCTSLCTSK | |
| SCHEMBL1091157 | 0.86 | TGM2 (0.93) | TGM2CTSBCTSSCTSLCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2007511607-A | — | — | 2007-05-10 | — | — | JP | claimed |
| EP-1706129-A1 | DRUG THERAPY FOR CELIAC SPRUE | The Board of Trustees of The Leland Stanford Junior University (US) | 2006-10-04 | — | — | EP | claimed |
| WO-2005049064-A1 | DRUG THERAPY FOR CELIAC SPRUE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2005-06-02 | — | — | WO | claimed |
| US-20080233102-A1 | Drug Therapy for Celiac Sprue | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2008-09-25 | — | — | US | disclosed |
| EP-1706129-A1 | DRUG THERAPY FOR CELIAC SPRUE | The Board of Trustees of The Leland Stanford Junior University (US) | 2006-10-04 | — | — | EP | disclosed |
| WO-2005049064-A1 | DRUG THERAPY FOR CELIAC SPRUE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080233102-A1 | Drug Therapy for Celiac Sprue | SI, DNPEP, SPINT2 | TGM2 13/4885CTSB 127/4885CTSS 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.